Compare Direxion Daily Semiconductor Bear 3X Shares (SOXS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bear 3X Shares vs Viatris Inc — how do they compare? Direxion Daily Semiconductor Bear 3X Shares trades at $44.81, while Viatris Inc trades at $16.5 (market cap $18.95B). The key difference: Viatris Inc pays a 2.91% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals.
| SOXS | VTRS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $1.29K | $17.86 |
52-Week Low | $32.50 | $9.49 |
Market Cap | — | $18.95B |
Enterprise Value | — | $31.07B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, trades at $44.09, down 4.86% in the past 24 hours amid a bearish technical signal. The stock is approaching key support at $43 after a 1:10 stock split effective July 15, 2026. Recent news highlights its volatility as an inverse ETF benefiting from semiconductor sector weakness, though technical indicators show mixed signals with RSI neutral and ADX suggesting a weakening trend.
The outlook remains highly speculative due to SOXS's leveraged inverse structure, which amplifies losses in rising markets. Risks include persistent AI-driven semiconductor demand and the ETF's decay over time. It is suited only for short-term tactical bearish bets, not long-term investment, with current sentiment cautioning against entry without clear technical breakdowns.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
